Sex: U
Vaccine: COVID19, UNK
Symptoms: COVID-19, Skin exfoliation
Clinical narrative: COVID-19; Peeling skin on right hand fingers; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) and SKIN EXFOLIATION (Peeling skin on right hand fingers) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 059H21A, 040B21A and 038A21A) for COVID-19 vaccination.  Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19.  Concurrent medical conditions included Breast cancer and Drug allergy (unspecified drug). Concomitant products included EXEMESTANE for an unknown indication.  In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In April 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jun-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) 1 dosage form. On 02-Jun-2022, the patient experienced SKIN EXFOLIATION (Peeling skin on right hand fingers). On an unknown date, the patient experienced COVID-19 (COVID-19). At the time of the report, COVID-19 (COVID-19) outcome was unknown and SKIN EXFOLIATION (Peeling skin on right hand fingers) had not resolved.  The patient received unspecified medications/products within 2 weeks of starting COVID-19 treatment. The patient received paxlovid for COVID-19 treatment. The device date was reported as 02-Jun-2022.  Company comment: This is a spontaneous case concerning a patient of unknown age and gender with relevant medical history of unspecified drug allergy and concurrent medical condition of breast cancer with concomitant medications of Exemestane since approximately 13 months ago and Nirmatrelvir + Ritonavir (Paxlovid). Patient has vaccine history of receiving first and second dose of mRNA-1273 vaccine with unspecified dosage interval. Patient experienced the unexpected non-serious event of Covid-19 and the unexpected non-serious event of skin exfoliation (peeling skin on right hand fingers). The events occurred approximately 6 months after the third dose of mRNA-1273 vaccine administration. The events were described as, approximately 6 months after the third dose of mRNA-1273 vaccine administration patient took Nirmatrelvir + Ritonavir (Paxlovid) for treatment of Covid-19. The day after, patient experienced peeling skin on right hand fingers and Paxlovid was discontinued the same day. No other information surrounding the events was reported. The outcome of the event Covid-19 was unknown while the event skin exfoliation (peeling skin on right hand fingers) was reported as not resolved. The current Covid-19 pandemic and concurrent medical condition of breast cancer remain confounders for the event Covid-19. The medical history of unspecified drug allergy and concomitant medications of Exemestane and Nirmatrelvir + Ritonavir (Paxlovid) remain confounders for the event skin exfoliation (peeling skin on right hand fingers). The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.  Reporter did not allow further contact; Sender's Comments: This is a spontaneous case concerning a patient of unknown age and gender with relevant medical history of unspecified drug allergy and concurrent medical condition of breast cancer with concomitant medications of Exemestane since approximately 13 months ago and Nirmatrelvir + Ritonavir (Paxlovid). Patient has vaccine history of receiving first and second dose of mRNA-1273 vaccine with unspecified dosage interval. Patient experienced the unexpected non-serious event of Covid-19 and the unexpected non-serious event of skin exfoliation (peeling skin on right hand fingers). The events occurred approximately 6 months after the third dose of mRNA-1273 vaccine administration. The events were described as, approximately 6 months after the third dose of mRNA-1273 vaccine administration patient took Nirmatrelvir + Ritonavir (Paxlovid) for treatment of Covid-19. The day after, patient experienced peeling skin on right hand fingers and Paxlovid was discontinued the same day. No other information surrounding the events was reported. The outcome of the event Covid-19 was unknown while the event skin exfoliation (peeling skin on right hand fingers) was reported as not resolved. The current Covid-19 pandemic and concurrent medical condition of breast cancer remain confounders for the event Covid-19. The medical history of unspecified drug allergy and concomitant medications of Exemestane and Nirmatrelvir + Ritonavir (Paxlovid) remain confounders for the event skin exfoliation (peeling skin on right hand fingers). The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.